Fegley Allison J, Tanski William J, Roztocil Elisa, Davies Mark G
Vascular Biology and Therapeutics Program, Division of Vascular Surgery, Department of Surgery, and Center for Cardiovascular Research, University of Rochester, Rochester, New York, USA
J Surg Res. 2003 Jul;113(1):32-41. doi: 10.1016/s0022-4804(03)00120-3.
Sphingosine-1-phosphate (S-1-P) is an extracellular mediator released in response to vessel injury. S-1-P binds to G-protein-coupled receptors, which can be Galpha(i)-, Galpha(q)-, or G(12/13)-linked. This study examines the role of p38 mitogen-activated protein kinase (p38(MAPK)) in vascular smooth muscle cell migration after stimulation with S-1-P, and pathways leading to p38(MAPK) activation. S-1-P has previously been shown to stimulate migration of vascular smooth muscle cells (VSMCs) in vitro through ERK1/2 and G(i). We hypothesized that S-1-P-induced VSMC migration is also dependent on p38(MAPK) activation through a G(i)-coupled extracellular receptor and phosphoinositide 3-kinase (PI3-K).
VSMCs were cultured in vitro. A linear wound assay was performed in the presence of S-1-P and inhibitors of p38(MAPK) (SB203580) or epidermal growth factor (EGF) receptor kinase (AG1478). Chemotaxis stimulated by S-1-P was also assayed in a modified Boyden chamber with and without SB203580 pretreatment. Western blotting was performed to examine p38(MAPK) activation in response to S-1-P with and without SB203580, AG1478, or inhibitors of G(i) (pertussis toxin), PI3-K (Wortmannin and LY294002), or MEK1 (PD98059). Western blotting and immunoprecipitation for targets of p38(MAPK) (MAPKAP kinase-2) and PI3-K (Akt) were also performed.S-1-P stimulated migration of VSMCs in both wound and Boyden transwell assays. This migration was inhibited by SB203580 to the level of control, whereas AG478 had no effect.
S-1-P stimulated activation of p38(MAPK) that peaked at 10 min, as well as activation of MAPKAP kinase-2. Activation of p38(MAPK) was significantly inhibited by SB203580, pertussis toxin, Wortmannin, and LY294002, but not by PD98059 or AG1478; MAPKAP kinase-2 activation was inhibited by SB203580. Akt was activated by S-1-P at 3 to 5 min; this response was inhibited by Wortmannin and LY294002, but not by SB203580 or pertussis toxin.
S-1-P induced VSMC migration through a G(i)-linked and a PI3-K coupled, p38(MAPK)- dependent process. PI3-K appears to function upstream of p38(MAPK), but was not G(i)-dependent. S-1-P-stimulated activation of p38(MAPK) does not signal via transactivation of the EGF receptor. Understanding signal transduction will allow targeted molecular interventions to treat the response of a vessel to injury.
1-磷酸鞘氨醇(S-1-P)是一种在血管损伤时释放的细胞外介质。S-1-P与G蛋白偶联受体结合,这些受体可以与Gα(i)、Gα(q)或G(12/13)相连。本研究探讨p38丝裂原活化蛋白激酶(p38(MAPK))在S-1-P刺激后血管平滑肌细胞迁移中的作用,以及导致p38(MAPK)激活的信号通路。先前已证明S-1-P通过ERK1/2和G(i)在体外刺激血管平滑肌细胞(VSMC)迁移。我们推测S-1-P诱导的VSMC迁移也依赖于通过G(i)偶联的细胞外受体和磷酸肌醇3激酶(PI3-K)激活p38(MAPK)。
体外培养VSMC。在S-1-P以及p38(MAPK)抑制剂(SB203580)或表皮生长因子(EGF)受体激酶抑制剂(AG1478)存在的情况下进行线性划痕试验。在改良的Boyden小室中,在有或没有SB203580预处理的情况下,检测S-1-P刺激的趋化作用。进行蛋白质印迹法以检测在有或没有SB203580、AG1478、G(i)抑制剂(百日咳毒素)、PI3-K抑制剂(渥曼青霉素和LY294002)或MEK1抑制剂(PD98059)的情况下,S-1-P刺激后p38(MAPK)的激活情况。还进行了针对p38(MAPK)靶点(MAPKAP激酶-2)和PI3-K靶点(Akt)的蛋白质印迹法和免疫沉淀。在划痕试验和Boyden小室迁移试验中,S-1-P均刺激了VSMC的迁移。这种迁移被SB203580抑制至对照水平,而AG478则无作用。
S-1-P刺激p38(MAPK)在10分钟时达到峰值激活,以及刺激MAPKAP激酶-2激活。SB203580、百日咳毒素、渥曼青霉素和LY294002可显著抑制p38(MAPK)的激活,但PD98059或AG1478则不能;SB203580可抑制MAPKAP激酶-2的激活。Akt在3至五分钟时被S-1-P激活;这种反应被渥曼青霉素和LY294002抑制,但不被SB203580或百日咳毒素抑制。
S-1-P通过G(i)连接和PI3-K偶联的、p38(MAPK)依赖的过程诱导VSMC迁移。PI3-K似乎在p38(MAPK)的上游起作用,但不依赖于G(i)。S-1-P刺激的p38(MAPK)激活不通过EGF受体的反式激活发出信号。了解信号转导将有助于进行有针对性的分子干预,以治疗血管对损伤的反应。